Adam Gerstenblith, MD
Retina Specialist · Hagerstown, MDNPI 1265654875
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $88,684 of the $106,970 with a category attached, or 82.9%. Regeneron Healthcare Solutions, Inc. accounts for 73.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $70,698 and has fallen 100.0% since, to $32 in 2025. Among retina specialist clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 99 payments — averaging $1080.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$79K
- AbbVie$23K
- US Retina LLC$5K
- Genentech USA, Inc.$214
- Bausch & Lomb Americas Inc.$35
- Novartis$35
- plus $64 from 2 others
Across 2,549 payments — averaging $3335.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$3.6M
- Ocular Therapeutix, Inc.$931K
- Apellis Pharmaceuticals, Inc.$894K
- Eyepoint US, Inc.$889K
- Bayer$888K
- Boehringer Ingelheim$519K
- plus $734K from 5 others
What the payments were for
- Speaking & faculty fees$88,68483%
- Travel & lodging$11,25811%
- Food & beverage$1,8262%
- Ownership interest$5,2025%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 53 | $78,660 |
| AbbVie | 30 | $22,760 |
| US Retina LLC | 6 | $5,202 |
| Genentech USA, Inc. | 4 | $214 |
| Bausch & Lomb Americas Inc. | 2 | $35 |
| Novartis | 2 | $35 |
| Apellis Pharmaceuticals, Inc. | 1 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$106,970 in reported general payments places this provider in the 95th percentile of 47 retina specialist providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 82 | $3,366 |
| Difluprednate | 15 | $1,586 |
| Bromfenac Sodium | 11 | $1,190 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 33 | $621 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 58 | $365 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 31 | $358 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Hagerstown
- Robert ParnesHagerstown$7K
- Adam WenickHagerstown$5K
- Erwin PuenteHagerstown$4K
- Rohit LakhanpalOwings Mills$168K
- Brian DoChevy Chase$116K
- Aziz KhanifarSilver Spring$83K
- Michael ElmanBaltimore$27K
- Reginald SandersGreenbelt$24K
- Sidney SchechetBaltimore$23K
- Mohsin AliGreenbelt$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.